BRAF and thyroid gland undifferentiated (anaplastic) carcinoma: Preclinical (transgenic mousemodels of BRAF V600E-mutant anaplastic thyroid cancer [ATC]) findings also indicatethat the combined inhibition of BRAF and MEK improve treatment response and preventMAPK pathway reactivation (13).